Skip to main content
SpringerLink
Log in

Botulinum Toxin A

  • Chapter
Book cover Das therapeutische Angebot für bewegungsgestörte Kinder

  • 223 Accesses

Zusammenfassung

Bereits der Name Botulinum Toxin A verrät viel über die Historie einer Substanz, die in den letzten Jahren eine sprunghafte Karriere vom Gift zum Arzneimittel erfahren hat. Bekannt geworden ist das Toxin als Verursacher des Botulismus, einer Lebensmittelvergiftung, die durch verdorbene Wurst- und Konservenwaren (Botulus lat. für Wurst) hervorgerufen wird. Im Jahr 1895 konnte das Bakterium Clostridium botulinum vom Mikrobiologen von Ermengem als Verursacher des Botulismus und Erzeuger des Botulinum Toxins identifiziert werden. Die wissenschaftliche Erstbeschreibung der Erkrankung geht 1817 auf den Arzt und Dichter Julius Kerner zurück, der erstaunlicherweise schon damals über einen therapeutischen Nutzen der Substanz spekulierte (Kerner 1817).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Arens LJ, Leary PM, Goldschmidt RB (1997) Experience with botulinum toxin in the treatment of cerebral palsy. S Afr Med J 87:1001–1003.

    PubMed  CAS  Google Scholar 

  • Bandmann O, Marsden CD, Wood NW (1998) Atypical presentations of dopa-responsive dystonia. Adv Neurol 78:283–290.

    PubMed  CAS  Google Scholar 

  • Blasi J, Chapman E, Link E, Binz T, Yamasaki S, De Camilli P, Südhof T, Niemann H (1993) Botulinum neurotoxin A selectively cleaves the synaptic protein. SNAP 25, Nature 365:160–163.

    Article  PubMed  CAS  Google Scholar 

  • Boyd K, Patterson V (1989) Dopa responsive dystonia: a treatable condition misdiag¬nosed as cerebral palsy. BMJ, 298:1019–1020.

    Article  PubMed  CAS  Google Scholar 

  • Calderon-Gonzalez R, Calderon-Sepulveda R, Rincon-Reyes M, Garcia-Ramirez J, Mino-Arango E (1994) Botulinum toxin A in management of cerebral palsy. Ped Neurol 10:284–288.

    Article  CAS  Google Scholar 

  • Chutorian AM, Root L (1994) Management of spasticity in children with Botulinum-A Toxin. International Pediatrics 9:35–43.

    Google Scholar 

  • Corry IS, Cosgrove AP, Walsh EG, McClean D, Graham HK (1997) Botulinum toxin A in the hémiplégie upper limb: a double-blind trial. Dev Med Child Neurol 39: 185–193.

    Article  PubMed  CAS  Google Scholar 

  • Corry IS, Cosgrove AP, Duffy CM, McNeill S, Taylor TC, Graham HK (1998) Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomised prospective trial. J Pediatr Orthop 18:304–311.

    Article  PubMed  CAS  Google Scholar 

  • Cosgrove AP, Corry IS, Graham HK (1994) Botulinum toxin in the management of the lower limb in cerebral palsy. Dev Med Child Neurol 36:386–396.

    Article  PubMed  CAS  Google Scholar 

  • de Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO (1999) Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 96:3200–3205.

    Article  PubMed  Google Scholar 

  • Deuschl G (1994) Botulinumtoxin zur Behandlung Hyperkinetischer Störungen. Arzneimitteltherapie 8:235–237.

    Google Scholar 

  • Eames NW, Baker R, Hill N, Graham K, Taylor T, Cosgrove A (1999) The effect of botu¬linum toxin A on gastrocnemius length: magnitude and duration of response. Dev Med Child Neurol 41:226–232.

    Article  PubMed  CAS  Google Scholar 

  • Flett PJ, Stern LM, Waddy H, Connell TM, Seeger JD, Gibson SK (1999) Botulinum toxin A versus fixed cast stretching for dynamic calf tightness in cerebral palsy. J Paediatr Child Health 35:71–77.

    Article  PubMed  CAS  Google Scholar 

  • Garcia RPJ, Sanchez BV, Urcelay V, San MV, Castillo F, Ferrer A, Campos J, Garcia de Y (1996) Botulinum A toxins in the treatment of spasticity in cerebral palsy during childhood. Neurologia 11:34–36.

    Google Scholar 

  • Gooch JL, Sandell TV (1996) Botulinum toxin for spasticity and athetosis in children with cerebral palsy. Arch Phys Med Rehabil 77:508–511.

    Article  PubMed  CAS  Google Scholar 

  • Greene P (1994) Controlled trials of botulinum toxin for cervical dystonia: a critical review. In: Jankowich J, Hallet M (eds) Therapy with Botulinum Toxin. Dekker, New York Basel Hong Kong, pp 279–287.

    Google Scholar 

  • Haley SM, Coster WJ, Ruth MF (1991). A Content Validity Study of the Pediatric Evaluation of Disability Inventory. Pediatric Physical Therapy 177–184.

    Google Scholar 

  • Hallett M (1999) One man’s poison—clinical applications of botulinum toxin. N Engl J Med 341:118–120.

    Article  PubMed  CAS  Google Scholar 

  • Hambleton P, Moore P (1997) Botulinum Neurotoxins: Origin, Structure, Molecular Actions and Antibodies. In: Moore P (ed) Botulinum Toxin Treatment. Blackwell Science Ltd, Oxford, Cambridge, pp 16–27.

    Google Scholar 

  • Heinen F, Mall V, Wissel J, Bernius P, Stücker R, Linder M, Philipsen A, Korinthenberg R (1997) Botulinum-Toxin A: Neue Möglichkeiten in der Behandlung spastischer Bewegungsstörungen. Monatsschrift Kinderheilkunde 145:1088–1092.

    Article  Google Scholar 

  • Heinen F, Wissel J, Philipsen A, Mall V, Leititis JU, Schenkel A, Stucker R, Korinthenberg R (1997) Interventional neuropediatrics: treatment of dystonic and spastic muscular hyperactivity with botulinum toxin A. Neuropediatrics 28:307–313.

    Article  PubMed  CAS  Google Scholar 

  • Heinen F, Wissel J, Mall V, Philipsen A, Korinthenberg R (1998) Interventionelle Neuropädiatrie: Behandlungsmöglichkeiten mit Botulinum Toxin A. Aktuelle Neuropädiatrie 1997:251–259.

    Google Scholar 

  • Heinen F, Linder M, Mall V, Kirschner J, Korinthenberg R (1999) Adductor spasticity in children with cerebral palsy and treatment with botulinum toxin type A—the parents’ view of functional outcome. European Journal of Neurology 6 (Suppl 4):47–50.

    Article  Google Scholar 

  • Kerner J (1817) Vergiftung durch verdorbene Würste. Tübinger Blätter für Naturwissenschaft und Arzneikunde 3:1–25.

    Google Scholar 

  • Koman LA, Mooney F, Smith B, Goodman A, Mulvaney T (1993) Management of cerebral palsy with botulinum A toxin: preliminary investigation. J Pediatr Orthop 13:489–495.

    Article  PubMed  CAS  Google Scholar 

  • Koman LA, Mooney JF, Smith BP, Goodman A, Mulvaney T (1994) Management of spasticity in cerebral palsy with botulinum-A toxin: report of a preliminary, randomized, double-blind trial. J Pediatr Orthop 14:299–303.

    Article  PubMed  CAS  Google Scholar 

  • Krageloh-Mann I, Hagberg G, Meisner C, Haas G, Eeg-Olofsson KE, Selbmann HK, Hagberg B, Michaelis R (1995) Bilateral spastic cerebral palsy—a collaborative study between southwest Germany and western Sweden. Ill: Aetiology. Dev Med Child Neurol 37:191–203.

    Article  CAS  Google Scholar 

  • Mall V, Heinen F, Linder M, Philipsen A, Korinthenberg R (1997) Treatment of cerebral palsy with botulinum toxin A: functional benefit and reduction of disability. Three case reports. Pediatric rehabilitation 1:235–237.

    CAS  Google Scholar 

  • Mall V, Heinen F, Kirschner J, Linder M, Stein S, Michaelis U, Bernius P, Lane M, Korinthenberg R (2000) Evaluation of botulinum toxin A therapy in children with adductor spasm by gross motor function measure. J Child Neurol 15 (4):214–217.

    Article  PubMed  CAS  Google Scholar 

  • Massin M, Allington N (1999) Role of exercise testing in the functional assessment of cerebral palsy children after botulinum A toxin injection. J Pediatr Orthop 19:362–365.

    Article  PubMed  CAS  Google Scholar 

  • Miller F, Bagg MR (1995) Age and migration percentage as risk factors for progression in spastic hip disease. Dev Med Child Neurol 37:449–455.

    Article  PubMed  CAS  Google Scholar 

  • Nygaard TG, Waran SP, Levine RA, Naini AB, Chutorian AM (1994) Dopa-responsive 172 dystonia simulating cerebral palsy. Pediatr Neurol 11:236–240.

    Article  PubMed  CAS  Google Scholar 

  • Palisano RJ (1993) Validity of goal attainment scaling in infants with motor delays. Phys Ther 73:651–658.

    PubMed  CAS  Google Scholar 

  • Pascual-Pascual SI, Sanchez de M, Roche MC, Pascual-Castroviejo I (1997) Botulinum toxin as a treatment for infantile cerebral palsy. Rev Neurol 25:1369–1375.

    PubMed  CAS  Google Scholar 

  • Russell DJ, Rosenbaum PL, Cadman DT, Gowland C, Hardy S, Jarvis S (1989) The gross motor function measure: a means to evaluate the effects of physical therapy. Dev Med Child Neurol 31:341–352.

    Article  PubMed  CAS  Google Scholar 

  • Sackett DL (1986) Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 95 (Suppl 2):2–4.

    Google Scholar 

  • Scott AB, Rosenbaum A, Collins CC (1973) Pharmacologic weakening of extraocular muscles. Invest Ophthalmol 12:924–927.

    PubMed  CAS  Google Scholar 

  • Scott AB (1980) Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 87:1044–1049.

    PubMed  CAS  Google Scholar 

  • Scrutton D, Rosenbaum P (1997) Locomotor development in children with cerebral palsy. In: Connolly KJ, Forssberg H (eds) Neurophysiology & neuropsychology of motor development, Vol 1. MacKeith Press, London, pp 101–123.

    Google Scholar 

  • Sutherland D, Kaufman K, Wyatt M, Chambers H (1996) Injection of botulinum A toxin into the gastrocnemius muscle of patients with cerebral palsy: a 3-dimensional motion analysis study.Gait & Posture 4:269–279.

    Article  Google Scholar 

  • Sutherland DH, Kaufman KR, Wyatt MP, Chambers HG, Mubarak SJ (1999) Double-blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy. Gait & Posture 10:1–9.

    Article  CAS  Google Scholar 

  • Tsui JK, Bhatt M, Calne S, Calne DB (1993) Botulinum toxin in the treatment of writer’s cramp: a double-blind study. Neurology 43:183–185.

    PubMed  CAS  Google Scholar 

  • Wall S, Chait LA, Temlett JA, Perkins B, Hillen G, Becker P (1993) Botulinum a chemodenervation: a new modality in cerebral palsied hands. Br J Plast Surg 46:703–706.

    Article  PubMed  CAS  Google Scholar 

  • Watanabe Y, Bakheit AM, McLellan DL (1998) A study of the effectiveness of botulinum toxin type A (Dysport) in the management of muscle spasticity. Disabil Rehabil 20:62–65.

    Article  PubMed  CAS  Google Scholar 

  • Wiegand H, Erdmann G, Wellhoner HH (1976) 1251-labelled botulinum a neurotoxin: pharmacokinetics in cats after intramuscular injection. Naunyn Schmiedebergs Arch Pharmacol 292 (2):161–165.

    Article  PubMed  CAS  Google Scholar 

  • Wissel J, Heinen F, Schenkel A, Doll B, Ebersbach G, Müller J, Poewe W (1999) Botulinum Toxin A in the Management of Spastic Gait Disorders in Children and Young Adults with Cerebral Palsy: A Randomized, Double-Blind Study of “High-Dose” versus “Low-Dose” Treatment. Neuropediatrics 30:120–124.

    Article  PubMed  CAS  Google Scholar 

  • Wissel J, Muller JJ, Heinen F, Mall V, Sojer M, Ebersbach G, Poewe W (1999) Safety and tolerance of single-dose botulinum toxin type A treatment in 204 patients with spasticity and localized associated symptoms. Austrian and German botulinum toxin A spasticity study group. Wien Klin Wochenschr 111:837–842.

    CAS  Google Scholar 

  • Wong V (1997) Use of botulinum toxin injection in 17 children with spastic cerebral palsy. Pediatr Neurol 18:124–131.

    Article  Google Scholar 

  • Zelnik N, Giladi N, Goikhman I, Keren G, Moris R, Honigman S (1997) The role of Botulinum Toxin in the Treatment of Lower Limb Spasticity in Children with Cerebral Palsy—A pilot study. Israel J Medical Sci 33:129–133.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Kinderheilkunde und Jugendmedizin, Klinikum Duisburg, Wedau Kliniken, Deutschland

    S. Berweck & F. Heinen

Authors
  1. V. Mall
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Herrmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Berweck
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Korinthenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F. Heinen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Ambulanz für Manuelle Medizin, Rheintalklinik, Im Rheintal 5, 79189, Bad Krozingen, Germany

    Henning Lohse-Busch  & Matthias Riedel  & 

  2. Deutsche Gesellschaft für Manuelle Medizin e.V., Ärzteseminar Hamm-Boppard (FAC) e.V., Obere Rheingasse 3, 56154, Boppard, Germany

    Toni Graf-Baumann

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Mall, V., Herrmann, J., Berweck, S., Korinthenberg, R., Heinen, F. (2001). Botulinum Toxin A. In: Lohse-Busch, H., Riedel, M., Graf-Baumann, T. (eds) Das therapeutische Angebot für bewegungsgestörte Kinder. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59567-7_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-59567-7_15

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-67917-2

  • Online ISBN: 978-3-642-59567-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation